Chronic Spontaneous Urticaria- Pipeline Insight, 2024

Chronic Spontaneous Urticaria- Pipeline Insight, 2024

DelveInsight’s, “Chronic Spontaneous Urticaria- Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Spontaneous Urticaria: Understanding

Chronic Spontaneous Urticaria: Overview

Urticaria (also called hives, wheals, or nettle rash) is characterized by pruritic, erythematous, and edematous wheals. Chronic Spontaneous Urticaria (CSU) is defined as hives that are present for at least or greater than 6 weeks and for the most days of the week. Chronic spontaneous urticaria is characterized by the presence of weals and angioedema. Weals can affect any site on the body and tend to be distributed widely. Chronic urticaria is diagnosed is based on a history lasting over 6 weeks of daily or episodic weals that last less than 24 hours without the presence of physical trigger factors. The international guidelines recommend limiting investigations in most patients with chronic spontaneous urticaria to differential blood count and erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Medicines for the treatment of chronic spontaneous urticarial are antihistamines, omalizumab, cyclosporine, and low-dose corticosteroids.

""Chronic Spontaneous Urticaria- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Spontaneous Urticaria pipeline landscape is provided which includes the disease overview and Chronic Spontaneous Urticaria treatment guidelines. The assessment part of the report embraces, in depth Chronic Spontaneous Urticaria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Spontaneous Urticaria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Spontaneous Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Spontaneous Urticaria.

Chronic Spontaneous Urticaria Emerging Drugs Chapters

This segment of the Chronic Spontaneous Urticaria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Spontaneous Urticaria Emerging Drugs

• Dupilumab: Sanofi

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.

Dupixent is approved for use in certain patients with atopic dermatitis, asthma, CRSwNP or EoE in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including chronic spontaneous urticaria, which is in the preregistration developmental stage.

• Tezepelumab: Amgen

Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP). The drug is in Preregistration for Asthma treatment; in Phase III for rhinosinusitis; in Phase II clinical studies for the treatment of chronic urticarial and chronic obstructive pulmonary disease. Tezepelumab is being developed in collaboration with AstraZeneca.

• Barzolvolimab: Celldex Therapeutics

Barzolvolimab (CDX-0159) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival, and activity of mast cells. In certain inflammatory diseases, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is being evaluated in the Phase II development stage for the treatment of chronic spontaneous urticaria.

Further product details are provided in the report……..

Chronic Spontaneous Urticaria: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Spontaneous Urticaria drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Chronic Spontaneous Urticaria

There are approx. 20+ key companies which are developing the therapies for Chronic Spontaneous Urticaria. The companies which have their Chronic Spontaneous Urticaria drug candidates in the most advanced stage, i.e. preregistration, Sanofi.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Spontaneous Urticaria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Spontaneous Urticaria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Spontaneous Urticaria drugs.

Chronic Spontaneous Urticaria Report Insights

• Chronic Spontaneous Urticaria Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Spontaneous Urticaria Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Spontaneous Urticaria drugs?
• How many Chronic Spontaneous Urticaria drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Spontaneous Urticaria?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Spontaneous Urticaria therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Spontaneous Urticaria and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• United BioPharma
• Teva Pharmaceuticals Development, Inc.
• Amgen
• Novartis Pharmaceuticals
• Allakos Inc.
• Sanofi
• Celltrion
• Celldex Therapeutics
• MICROBIO GROUP.
• Escient Pharmaceuticals
• Jasper Therapeutics
• Glenmark Pharmaceuticals
• Taiho Pharmaceuticals
• ValenzaBio
• Carna Biosciences
• Servier

Key Products

• LOU064
• Dupilumab
• Barzolvolimab
• UB221
• Lirentelimab
• CT-P39
• Tezepelumab
• TEV-45779
• FB-31
• Briquilimab
• GBR 310
• TAS5315
• EP 262
• Anti-CD40